Pre- and postoperative characteristics of metabolic syndrome in patients with colorectal cancer

Jasna Gačić, Vesna Dimitrijević-Srećković, Dragan Gačić, Simona Petričević, Branko Srećković, Bratislav Lazić, Aleksandar Đorđević, Blagoje Đukanović, Tomislav Ranđelović

Abstract


The pathological mechanisms that link the metabolic syndrome (MS) and colorectal cancer (CRC) are most probably related to abdominal obesity and insulin resistance. This study aimed to assess the relationship between MS and its clinical characteristics, with CRC. We investigated the changes in the appearance of MS features three months after surgical treatment, and its relationship with the concentration of tumor and inflammation markers. The retrospective cohort study was performed on 193 patients who were diagnosed with CRC and consequently surgically treated (at the Department of General Surgery, Clinical Hospital Center “Bežanijska kosa”, Belgrade). The included patients were divided into two groups based on the presence of MS. Body mass index (BMI), waist circumference, blood pressure, blood glucose, triglycerides (TG), high density lipoproteins – cholesterol (HDL-C), carcinoembryonic antigen (CEA), α-fetoprotein (AFP), carbohydrate antigen 19-9 (CA 19-90) and C-reactive protein (CRP) were analyzed at the time when the CRC diagnosis was made and three months after surgery. We observed a significant decrease in the number of patients with MS three months postoperatively compared to the number of patients in the preoperative period (106 versus 81; p<0.001). CRP levels were significantly decreased postoperatively compared to the preoperative period in patients with MS (p<0.001). AFP concentrations were significantly decreased (p<0.001), while CEA and CA 19-9 were significantly increased postoperatively compared to preoperatively (p<0.001, p<0.001). Further studies should be conducted in order to examine the influence of MS and its characteristics solely on CRC prognosis and its overall effect on CRC treatment.

https://doi.org/10.2298/ABS160608079G

Received: June 8, 2016; Revised: June 15, 2016; Accepted: June 16, 2016; Published online: September 14, 2016

How to cite this article: Gačić J, Dimitrijević-Srećković V, Gačić D, Petričević S, Srećković B, Lazić B, Đorđević A, Đukanović B, Ranđelović T. Pre- and postoperative characteristics of metabolic syndrome in patients with colorectal cancer. Arch Biol Sci. 2017;69(2):215-22.


Keywords


metabolic syndrome; colorectal neoplasms; preoperative period; postoperative period; biomarkers

Full Text:

PDF

References


Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol. 2006;21(1):1-6.

Parapid B, Ostojic MC, Lalic NM, Micic D, Damjanovic S, Bubanja D, Simic D, Lalic K, Polovina S, Marinkovic J, Milic NM. Risk factors clustering within the metabolic syndrome: a pattern or by chance? Hellenic J Cardiol. 2014;55(2):92-100.

DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14(3):173-94.

Lindsay RS Howard BV. Cardiovascular risk associated with the metabolic syndrome. Curr Diab Rep. 2004;4(1):63-8.

Cowey S, Hardy RW. The metabolic syndrome: A high-risk state for cancer? Am J Pathol. 2006;169(5):1505-22.

Mendonça FM, de Sousa FR, Barbosa AL, Martins SC, Araújo RL, Soares R, Abreu C. Metabolic syndrome and risk of cancer: which link? Metabolism. 2015;64(2):182-9.

Colangelo LA, Gapstur SM, Gann PH, Dyer AR, Liu K. Colorectal cancer mortality and factors related to the insulin resistance syndrome. Cancer Epidemiol Biomarkers Prev. 2002;11(4):385-91.

Trevisan M, Liu J, Muti P, Misciagna G, Menotti A, Fucci F; Risk Factors and Life Expectancy Research Group. Markers of insulin resistance and colorectal cancer mortality. Cancer Epidemiol Biomarkers Prev. 2001;10(9):937-41.

Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Rafaniello C, Panagiotakos DB, Giugliano D. Colorectal cancer association with metabolic syndrome and its components: a systematic review with meta-analysis. Endocrine. 2013;44(3):634-47.

Jinjuvadia R, Lohia P, Jinjuvadia C, Montoya S, Liangpunsakul S. The association between metabolic syndrome and colorectal neoplasm: systemic review and meta-analysis. J Clin Gastroenterol 2013;47(1):33-44.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-E386.

Krivokapić Z, Ćeranić M, Šaranović Đ, Stanojević G, Tripković I, Bulajić M, Galun D, Radosavljević D, Breberina M. Nacionalni vodič dobre kliničke prakse za dijagnostikovanje i lečenje raka kolona i rektuma. Beograd: Agencija za akreditaciju zdravstvenih ustanova Srbije; 2012. Available from: http://www.zdravlje.gov.rs/showpage.php?id=145.

Yang DX, Gross CP, Soulos PR, Yu JB. Estimating the magnitude of colorectal cancers prevented during the era of screening: 1976 to 2009. Cancer. 2014;120(18):2893-901.

Newton KF, Newman W, Hill J. Review of biomarkers in colorectal cancer. Colorectal Dis. 2012;14(1):3-17.

Duffy MJ, van Dalen A, Haglund C, Hansson L, Klapdor R, Lamerz R, Nilsson O, Sturgeon C, Topolcan O. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer. 2003;39(6):718-27.

Tarantino I, Warschkow R, Schmied BM, Güller U, Mieth M, Cerny T, Büchler MW, Ulrich A. Predictive Value of CEA for Survival in Stage I Rectal Cancer: a Population-Based Propensity Score-Matched Analysis. J Gastrointest Surg. 2016;20(6):1213-22.

Li YH, An X, Xiang XJ, Wang ZQ, Wang FH, Feng F, Jiang WQ, He YJ, Xu RH. Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy. Ai Zheng. 2009;28(9):939-44.

Sajid KM, Parveen R, Durr-e-Sabih RM, Chaouachi K, Naeem A, Mahmood R, Shamim R. Carcinoembryonic antigen (CEA) levels in hookah smokers, cigarette smokers and non-smokers. J Pak Med Assoc. 2007;57(12):595-9.

Nakamura N, Aoji O, Yoshikawa T, Mori K, Kajiyama S, Kitagawa Y, Kanatsuna T, Kondo M. Elevated serum CA19-9 levels in poorly controlled diabetic patients. Jpn J Med. 1986;25(3):278-80.

Lorenzo C, Williams K, Hunt JK, Haffner MS. The National Cholesterol Education Program-Adult Treatment Panel III, International Diabetes Federation, and World Health Organization Definitions of the Metabolic Syndrome as Predictors of Incident Cardiovascular Disease and Diabetes. Diabetes Care. 2007;30(1):8-13.

Souza MR, Diniz M, Medeiros-Filho JE, Araujo MS. Metabolic syndrome and risk factors for nonalcoholic fatty liver disease. Arq Gastroenterol. 2012;49(1):89-96.

Savva SC, Lamnisos D, Kafatos AG. Predicting cardiometabolic risk: waist-to-height ratio or BMI. A meta-analysis. Diabetes Metab Syndr Obes. 2013;6:403-19.

Yamada T, Hara K, Kadowaki T. Chewing betel quid and the risk of metabolic disease, cardiovascular disease, and all-cause mortality: a meta-analysis. PLoS One. 2013; 8(8):e70679.

American Cancer Society. Cancer Facts & Figures 2012. Atlanta: American Cancer Society; 2012.

Friedenreich CM. Physical activity and cancer prevention: from observational to intervention research. Cancer Epidemiol Biomarkers Prev. 2001;10(4):287-301.

Ogden C, Carroll M, Kit B, Flegal K. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. JAMA. 2012;307(5):483-90.

Sowers JR. Obesity as a cardiovascular risk factor. Am J Med. 2003;115(Suppl 8A):37S-41S.

Kim JY, Jung YS, Park JH, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Choi KY, Park DI. Different risk factors for advanced colorectal neoplasm in young adults. World J Gastroenterol. 2016;22(13):3611-20.

Ahmed RL, Schmitz KH, Anderson KE, Rosamond WD, Folsom AR. The metabolic syndrome and risk of incident colorectal cancer. Cancer. 2006;107(1):28-36.

Grossman E, Messerli FH, Boyko V, Goldbourt U. Is there an association between hypertension and cancer mortality? Am J Med. 2002;112(6):479-86.

Park SK, Joo JS, Kim DH, Kim YE, Kang D, Yoo KY. Association of serum lipids and glucose with the risk of colorectal adenomatous polyp in men: a case-control study in Korea. J Korean Med Sci. 2000;15(6):690-5.

Tabuchi M, Kitayama J, Nagawa H. Hypertriglyceridemia is positively correlated with the development of colorectal tubular adenoma in Japanese men. World J Gastroenterol. 2006;12(8):1261-4.

Bird CL, Ingles SA, Frankl HD, Lee ER, Longnecker MP, Haile RW. Serum lipids and adenomas of the left colon and rectum. Cancer Epidemiol Biomarkers Prev. 1996;5(8):607-12.

Bayerdorffer E, Mannes GA, Richter WO, Ochsenkühn T, Seeholzer G, Köpcke W, Wiebecke B, Paumgartner G. Decreased high-density lipoprotein cholesterol and increased low-density cholesterol levels in patients with colorectal adenomas. Ann Intern Med. 1993;118(7):481-7.

Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst. 2005;97(22):1679-87.

Berstein LM, Kvatchevskaya JO, Poroshina TE, Kovalenko IG, Tsyrlina EV, Zimarina TS, Ourmantcheeva AF, Ashrafian L, Thijssen JH. Insulin resistance, its consequences for the clinical course of the disease, and possibilities of correction in endometrial cancer. J Cancer Res Clin Oncol. 2004;130(11):687-93.

Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr. 2001;131(11Suppl):3109S-3120S.

Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, Hartwick W, Hoffman B, Hood N. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol. 2002;20(1):42-51.

Hammarsten J, Hogstedt B. Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer. Blood Press. 2004;13(1):47-55.

Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625-38.

Valko M, Izakovic M, Mazur M, Rhodes CJ, Telser J. Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem. 2004;266(1-2):37-56.

Cejas P, Casado E, Belda-Iniesta C, De Castro J, Espinosa E, Redondo A, Sereno M, Garcia-Cabezas MA, Vara JA, Dominguez-Caceres A, Perona R, Gonzalez-Baron M: Implications of oxidative stress and cell membrane lipid peroxidation in human cancer. Cancer Causes Control. 2004;15(7):707-19.

Okorodudu DO, Jumean MF, Montori VM, Romero-Corral A, Somers VK, Erwin PJ, Lopez-Jimenez F. Diagnostic performance of body mass index to identify obesity as defined by body adiposity: a systematic review and meta-analysis. Int J Obes (Lond). 2010; 34(5):791-9.

Pischon T, Lahmann PH, Boeing H, Friedenreich C, Norat T, Tjonneland A, Halkjaer J, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, Guernec G, Bergmann MM, Linseisen J, Becker N, Trichopoulou A, Trichopoulos D, Sieri S, Palli D, Tumino R, Vineis P, Panico S, Peeters PH, Bueno-de-Mesquita HB, Boshuizen HC, Van Guelpen B, Palmqvist R, Berglund G, Gonzalez CA, Dorronsoro M, Barricarte A, Navarro C, Martinez C, Quirós JR, Roddam A, Allen N, Bingham S, Khaw KT, Ferrari P, Kaaks R, Slimani N, Riboli E. Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst. 2006; 98(13):920-31.

Kim BC, Shin A, Hong CW, Sohn DK, Han KS, Ryu KH, Park BJ, Nam JH, Park JW, Chang HJ, Choi HS, Kim J, Oh JH. Association of colorectal adenoma with components of metabolic syndrome. Cancer Causes Control. 2012;23(5):727-35.

Liu CS, Hsu HS, Li CI, Jan CI, Li TC, Lin WY, Lin T, Chen YC, Lee CC, Lin CC. Central obesity and atherogenic dyslipidemia in metabolic syndrome are associated with increased risk for colorectal adenoma in a Chinese population. BMC Gastroenterol. 2010;10:51.

Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol. 2010;316(2):129-39.

Trayhurn P, Beattie JH. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc. 2001;60(3):329-39.

Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol. 2004;15(11):2792-800.

Roberts DL, Dive C, Renehan AG. Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med. 2010;61:301-16.

Itzkowitz SH. Cancer prevention in patients with inflammatory bowel disease. Gastroenterol Clin North Am. 2002;31(4):1133-44.

Fayh AP, Lopes AL, da Silva AM, Reischak-Oliveira A, Friedman R. Effects of 5% weight loss through diet or diet plus exercise on cardiovascular parameters of obese: a randomized clinical trial. Eur J Nutr. 2013;52(5):1443-50.

Pendyala S, Neff LM, Suarez-Farinas M, Holt PR. Diet-induced weight loss reduces colorectal inflammation: implications for colorectal carcinogenesis. Am J Clin Nutr. 2011;93(2):234-42.

Rockall TA, McDonald PJ. Carcinoembryonic antigen: its value in the follow-up of patients with colorectal cancer. Int J Colorectal Dis. 1999;14(1):73-7.

Herrera MA, Chu TM, Holyoke ED. Carcinoembryonic antigen (CEA) as a prognostic and monitoring test in clinically complete resection of colorectal carcinoma. Ann Surg. 1976;183(1):5-9.

Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet. 1979;5(6):957-71.

Filella X, Molina R, Grau JJ, Pique M, Garcia-Valdecasas JC, Astudillo E, Biete A, Bordas JM, Novell A, Campo E, Ballesta AM. Prognostic value of CA 19.9 levels in colorectal cancer. Ann Surg. 1992;216(1):55-9.

Abelev GI, Perova SD, Khramkova NI, Postnikova ZA, Irlin IS. Production of embryonal alpha-globulin by transplantable mouse hepatomas. Transplantation. 1963;1:174-80.

McIntire KR, Waldmann TA, Moertel CG, Go VL. Serum α-fetoprotein in patients with neoplasms of the gastrointestinal tract. Cancer Res. 1975;35(4):991-6.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2017 ARCHIVES OF BIOLOGICAL SCIENCES

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.